1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Virobay Inc. - Product Pipeline Review - 2015

Virobay Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 33 pages

Virobay Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Virobay Inc. - Product Pipeline Review - 2015’, provides an overview of the Virobay Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Virobay Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Virobay Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Virobay Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Virobay Inc.’s pipeline products

Reasons to buy

- Evaluate Virobay Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Virobay Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Virobay Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Virobay Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Virobay Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Virobay Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Virobay Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Virobay Inc. Snapshot 5
Virobay Inc. Overview 5
Key Information 5
Key Facts 5
Virobay Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Virobay Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Virobay Inc. - Pipeline Products Glance 13
Virobay Inc. - Clinical Stage Pipeline Products 13
Phase I Products/Combination Treatment Modalities 13
Phase 0 Products/Combination Treatment Modalities 14
Virobay Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Virobay Inc. - Drug Profiles 17
VBY-036 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
VBY-129 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
VBY-376 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
VBY-285 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
VBY-825 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
VBY-50365 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
VBY-X 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Small Molecule to Inhibit Cathepsin Protease for Cancer 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Virobay Inc. - Pipeline Analysis 25
Virobay Inc. - Pipeline Products by Target 25
Virobay Inc. - Pipeline Products by Route of Administration 26
Virobay Inc. - Pipeline Products by Molecule Type 27
Virobay Inc. - Pipeline Products by Mechanism of Action 28
Virobay Inc. - Recent Pipeline Updates 29
Virobay Inc. - Dormant Projects 30
Virobay Inc. - Locations And Subsidiaries 31
Head Office 31
Other Locations and Subsidiaries 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables
Virobay Inc., Key Information 5
Virobay Inc., Key Facts 5
Virobay Inc. - Pipeline by Indication, 2015 8
Virobay Inc. - Pipeline by Stage of Development, 2015 9
Virobay Inc. - Monotherapy Products in Pipeline, 2015 10
Virobay Inc. - Out-Licensed Products in Pipeline, 2015 11
Virobay Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 12
Virobay Inc. - Phase I, 2015 13
Virobay Inc. - Phase 0, 2015 14
Virobay Inc. - Preclinical, 2015 15
Virobay Inc. - Discovery, 2015 16
Virobay Inc. - Pipeline by Target, 2015 25
Virobay Inc. - Pipeline by Route of Administration, 2015 26
Virobay Inc. - Pipeline by Molecule Type, 2015 27
Virobay Inc. - Pipeline Products by Mechanism of Action, 2015 28
Virobay Inc. - Recent Pipeline Updates, 2015 29
Virobay Inc. - Dormant Developmental Projects,2015 30
Virobay Inc., Other Locations 31

List of Figures
Virobay Inc. - Pipeline by Top 10 Indication, 2015 7
Virobay Inc. - Pipeline by Stage of Development, 2015 9
Virobay Inc. - Monotherapy Products in Pipeline, 2015 10
Virobay Inc. - Out-Licensed Products in Pipeline, 2015 11
Virobay Inc. - Pipeline by Top 10 Target, 2015 25
Virobay Inc. - Pipeline by Top 10 Route of Administration, 2015 26
Virobay Inc. - Pipeline by Top 10 Molecule Type, 2015 27
Virobay Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.